Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 in Subjects Who Have Completed Study 1001

Trial Profile

Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 in Subjects Who Have Completed Study 1001

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Andromeda Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 08 Sep 2014 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2014, according to a Hyperion Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top